Citadel Advisors
MIRM icon

Citadel Advisors’s Mirum Pharmaceuticals MIRM Stock Holding History

Citadel Advisors’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.06M Sell
11,500
-1,200
-9% -$113K ﹤0.01% 7523
2025
Q4 		$1M Sell
12,700
-300
-2% -$21.5K ﹤0.01% 7382
2025
Q3 		$953K Buy
13,000
+7,100
+120% +$451K ﹤0.01% 7635
2025
Q2 		$300K Sell
5,900
-8,900
-60% -$396K ﹤0.01% 9827
2025
Q1 		$667K Buy
14,800
+12,200
+469% +$575K ﹤0.01% 7834
2024
Q4 		$108K Sell
2,600
-41,500
-94% -$1.73M ﹤0.01% 11371
2024
Q3 		$1.72M Buy
44,100
+19,400
+79% +$774K ﹤0.01% 5819
2024
Q2 		$844K Buy
24,700
+3,100
+14% +$81.3K ﹤0.01% 6939
2024
Q1 		$543K Buy
21,600
+11,100
+106% +$305K ﹤0.01% 8202
2023
Q4 		$310K Buy
10,500
+3,300
+46% +$99.9K ﹤0.01% 9095
2023
Q3 		$228K Sell
7,200
-7,500
-51% -$205K ﹤0.01% 9667
2023
Q2 		$380K Sell
14,700
-5,400
-27% -$144K ﹤0.01% 8520
2023
Q1 		$483K Sell
20,100
-1,500
-7% -$34.2K ﹤0.01% 8393
2022
Q4 		$421K Buy
21,600
+4,000
+23% +$79.1K ﹤0.01% 8597
2022
Q3 		$370K Buy
+17,600
New +$424K ﹤0.01% 9116
2022
Q2 		– Sell
-24,900
Closed -$548K – 13632
2022
Q1 		$548K Sell
24,900
-8,900
-26% -$182K ﹤0.01% 9164
2021
Q4 		$539K Buy
33,800
+4,200
+14% +$65.3K ﹤0.01% 9511
2021
Q3 		$590K Buy
+29,600
New +$481K ﹤0.01% 9465

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Citadel Advisors's MIRM Position: Q1 2026 in Review

Citadel Advisors increased its Mirum Pharmaceuticals (MIRM) stake by 25% in Q1 2026, buying an estimated $19.9M and bringing the position to 1,052,048 shares worth $97.2M. The position accounts for 0.02% of the portfolio, ranked #826.

Citadel Advisors first reported a position in MIRM in Q2 2020 and has held it in 22 quarters since. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

  • Citadel Advisors held 1,052,048 shares of Mirum Pharmaceuticals worth $97.2M as of Q1 2026.
  • Citadel Advisors bought 211,828 Mirum Pharmaceuticals shares in Q1 2026, an estimated $19.9M.
  • Mirum Pharmaceuticals made up 0.02% of Citadel Advisors's portfolio in Q1 2026, its #826 holding.
  • Citadel Advisors first reported a position in Mirum Pharmaceuticals in Q2 2020 and has held it in 22 quarters since.
  • 311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.